ImmVira has concluded the Phase I clinical trial of its oncolytic product, MVR-T3011 IV, to treat patients with various kinds of late-stage tumours in the US.
A three-in-one genetically engineered oncolytic herpes simplex virus (oHSV), MVR-T3011 is administered intravenously (IV).
Go deeper with GlobalData
According to the trial findings, the product showed encouraging safety and initial efficacy for some indications.
As of 31 October 2023, 94.4% of trial subjects reported treatment-emergent adverse events (TEAEs) while 88.89% had treatment-related adverse events (TRAEs) linked to the drug.
All the reported adverse events were of grade 1 or 2 severity in nature without any TRAEs of Grade 3 or higher reported.
Overall, an IV dose of MVR-T3011 demonstrated a safety profile in the trial.
Based on RECIST 1.1 criteria, subjects with cancer of appendices, endometrium and gallbladder showed a substantial decline in tumour burden.
ImmVira chairwoman and CEO Dr Grace Guoying Zhou said: “The development of intravenously administered oncolytic virus products has long been a challenging bottleneck.
“Oncolytic viruses must overcome numerous hurdles, such as neutralisation by antibodies or the risk of cytokine storms, in order to effectively reach tumour sites with a sufficient number of viruses to achieve anti-tumour effects.
“With the successful Phase I clinical study results of MVR-T3011 IV, a global-first clinical-stage intravenous oHSV product, our company is now fully confident and committed to expediting clinical explorations in colorectal cancer, non-small cell lung cancer, and other indications, including combination treatments with immune checkpoint inhibitor or chemotherapy.”
